APOC3 and diabetes mellitus: Therefore, understanding how APOC3 affects the metabolism of TRLs and contributes to diabetes-related CVD is essential for developing potential therapeutic strategies, including monoclonal antibodies and small interfering RNA (siRNA) therapies aimed at reducing the APOC3 levels [18].